938 related articles for article (PubMed ID: 18172390)
1. Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: a 3-year follow-up study.
Ruan Y; Qin G; Yin L; Chen K; Qian HZ; Hao C; Liang S; Zhu J; Xing H; Hong K; Shao Y
AIDS; 2007 Dec; 21 Suppl 8():S39-46. PubMed ID: 18172390
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of harm reduction programs on seroincidence of HIV, hepatitis B and C, and syphilis among intravenous drug users in southwest China.
Ruan Y; Liang S; Zhu J; Li X; Pan SW; Liu Q; Song B; Wang Q; Xing H; Shao Y
Sex Transm Dis; 2013 Apr; 40(4):323-8. PubMed ID: 23486498
[TBL] [Abstract][Full Text] [Related]
3. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users.
Van Den Berg C; Smit C; Van Brussel G; Coutinho R; Prins M;
Addiction; 2007 Sep; 102(9):1454-62. PubMed ID: 17697278
[TBL] [Abstract][Full Text] [Related]
4. Frontloading: a risk factor for HIV and hepatitis C virus infection among injecting drug users in Berlin.
Stark K; Müller R; Bienzle U; Guggenmoos-Holzmann I
AIDS; 1996 Mar; 10(3):311-7. PubMed ID: 8882671
[TBL] [Abstract][Full Text] [Related]
5. [Prevalence of HIV and hepatitis B and C among drug addicts in the city of Copenhagen].
Fuglsang T; Fouchard JR; Ege PP
Ugeskr Laeger; 2000 Jul; 162(27):3860-4. PubMed ID: 10920701
[TBL] [Abstract][Full Text] [Related]
6. Needle exchange use, sexual risk behaviour, and the prevalence of HIV, hepatitis B virus, and hepatitis C virus infections among Bulgarian injection drug users.
Vassilev ZP; Hagan H; Lyubenova A; Tomov N; Vasilev G; Krasteva D; Des Jarlais DC
Int J STD AIDS; 2006 Sep; 17(9):621-6. PubMed ID: 16942654
[TBL] [Abstract][Full Text] [Related]
7. Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia.
Miller ER; Hellard ME; Bowden S; Bharadwaj M; Aitken CK
J Infect; 2009 May; 58(5):375-82. PubMed ID: 19328555
[TBL] [Abstract][Full Text] [Related]
8. Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in south-western Sydney, Australia.
Maher L; Chant K; Jalaludin B; Sargent P
J Gastroenterol Hepatol; 2004 Oct; 19(10):1114-20. PubMed ID: 15377287
[TBL] [Abstract][Full Text] [Related]
9. Relevance of intravenous cocaine use in relation to prevalence of HIV, hepatitis B and C virus markers among intravenous drug abusers in southern Italy.
Guadagnino V; Zimatore G; Izzi A; Caroleo B; Rocca A; Montesano F; Costa C; Masciari R; Naso E; Biselli R
J Clin Lab Immunol; 1995; 47(1):1-9. PubMed ID: 8735431
[TBL] [Abstract][Full Text] [Related]
10. Molecular epidemiology of HCV monoinfection and HIV/HCV coinfection in injection drug users in Liuzhou, Southern China.
Tan Y; Wei QH; Chen LJ; Chan PC; Lai WS; He ML; Kung HF; Lee SS
PLoS One; 2008; 3(10):e3608. PubMed ID: 18974888
[TBL] [Abstract][Full Text] [Related]
11. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users.
van den Berg CH; Smit C; Bakker M; Geskus RB; Berkhout B; Jurriaans S; Coutinho RA; Wolthers KC; Prins M
Eur J Epidemiol; 2007; 22(3):183-93. PubMed ID: 17334821
[TBL] [Abstract][Full Text] [Related]
12. Sexual and other noninjection risks for HBV and HCV seroconversions among noninjecting heroin users.
Neaigus A; Gyarmathy VA; Zhao M; Miller M; Friedman SR; Des Jarlais DC
J Infect Dis; 2007 Apr; 195(7):1052-61. PubMed ID: 17330797
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C, B, and human immunodeficiency virus infections in illicit drug users in Israel: prevalence and risk factors.
Loebstein R; Mahagna R; Maor Y; Kurnik D; Elbaz E; Halkin H; Olchovsky D; Ezra D; Almog S
Isr Med Assoc J; 2008 Nov; 10(11):775-8. PubMed ID: 19070285
[TBL] [Abstract][Full Text] [Related]
14. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia.
Maher L; Jalaludin B; Chant KG; Jayasuriya R; Sladden T; Kaldor JM; Sargent PL
Addiction; 2006 Oct; 101(10):1499-508. PubMed ID: 16968352
[TBL] [Abstract][Full Text] [Related]
15. Coinfection with HIV and hepatitis C virus among injection drug users in southern China.
Garten RJ; Zhang J; Lai S; Liu W; Chen J; Yu XF
Clin Infect Dis; 2005 Jul; 41 Suppl 1():S18-24. PubMed ID: 16265609
[TBL] [Abstract][Full Text] [Related]
16. Minimal transmission of HIV despite persistently high transmission of hepatitis C virus in a Swedish needle exchange program.
Blomé MA; Björkman P; Flamholc L; Jacobsson H; Molnegren V; Widell A
J Viral Hepat; 2011 Dec; 18(12):831-9. PubMed ID: 21114587
[TBL] [Abstract][Full Text] [Related]
17. [Risk reduction and intravenous drug use abstinence in patients with HIV infection. The SEROCO group].
Meyer L; Wade A; Persoz A; Boué F; Dellamonica P; Caroli-Bosc C; Carré N
Rev Epidemiol Sante Publique; 1998 Feb; 46(1):34-9. PubMed ID: 9533232
[TBL] [Abstract][Full Text] [Related]
18. A syringe exchange programme in prison as prevention strategy against HIV infection and hepatitis B and C in Berlin, Germany.
Stark K; Herrmann U; Ehrhardt S; Bienzle U
Epidemiol Infect; 2006 Aug; 134(4):814-9. PubMed ID: 16371183
[TBL] [Abstract][Full Text] [Related]
19. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users.
Miller CL; Johnston C; Spittal PM; Li K; Laliberté N; Montaner JS; Schechter MT
Hepatology; 2002 Sep; 36(3):737-42. PubMed ID: 12198668
[TBL] [Abstract][Full Text] [Related]
20. A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users.
Garfein RS; Golub ET; Greenberg AE; Hagan H; Hanson DL; Hudson SM; Kapadia F; Latka MH; Ouellet LJ; Purcell DW; Strathdee SA; Thiede H;
AIDS; 2007 Sep; 21(14):1923-32. PubMed ID: 17721100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
